natgillin/translations-raw huggingface dataset:
Before you take, or whilst you are taking Ipreziv, tell your doctor if you: - have kidney problems - are on dialysis or had a recent kidney transplant 
Prije nego što uzmete ili dok uzimate Ipreziv, obavijestite svog liječnika: - ako imate tegobe s bubrezima
Fumaric acid (E 297) Sodium hydroxide Hydroxypropylcellulose (E 463) Croscarmellose sodium Cellulose, microcrystalline (E 460) Magnesium stearate (E 572) 
6.1 Popis pomoćnih tvari manitol (E 421) fumarna kiselina (E 297) natrijev hidroksid hidroksipropilceluloza (E 463) karmelozanatrij, umrežena celuloza, mikrokristalična (E 460) magnezijev stearat (E 572)
Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE inhibitor with an angiotensin II receptor blocker. 
ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) i VA NEPHRON-D (eng. The Veterans Affairs Nephropathy in Diabetes)) ispitivala su primjenu kombinacije ACE inhibitora s blokatorom angiotenzin II receptora.
When Ipreziv is taken with chlortalidone (a water tablet), higher levels of certain chemicals in the blood (such as creatinine), which are indicators of kidney function, have been seen commonly (in less than 1 in 10 users), and low blood pressure is also common. 
Kad se Ipreziv uzima s klortalidonom (tableta za mokrenje), često (u manje od 1 na 10 korisnika) se opažaju više razine određenih biokemijskih tvari u krvi (kao što je kreatinin), koje su pokazatelji funkcije bubrega, a i nizak krvni tlak česti je nalaz.
MINIMUM PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Blister pack 
PODACI KOJE MORA NAJMANJE SADRŽAVATI UNUTARNJE PAKIRANJE Blister pakiranje
IPREZIV 20 MG TABLETS IPREZIV 40 MG TABLETS IPREZIV 80 MG TABLETS 
IPREZIV 20 MG TABLETE IPREZIV 40 MG TABLETE IPREZIV 80 MG TABLETE
In active-comparator studies with either valsartan or ramipril, the blood-pressure-lowering effect with Ipreziv was sustained during long-term treatment. 
U ispitivanjima s aktivnom kontrolom pomoću valsartana ili ramiprila, učinak Ipreziva na sniženje krvnog tlaka bio je održan tijekom dugotrajnog liječenja.
As with other angiotensin II receptor antagonists the combination of lithium and Ipreziv is not recommended (see section 4.5). 
Kao i za druge antagoniste receptora angiotenzina II, ne preporučuje se kombinacija litija i Ipreziva (vidjeti dio 4.5).
Do not use Ipreziv after the expiry date which is stated on the carton after EXP. 
Ipreziv se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji iza “Rok valjanosti”.
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy Special caution is indicated in patients suffering from aortic or mitral valve stenosis, or hypertrophic obstructive cardiomyopathy (HOCM). 
Aortalna i mitralna stenoza, opstruktivna hipertrofična kardiomiopatija Indiciran je poseban oprez u bolesnika koji boluju od aortalne ili mitralne stenoze ili hipertrofične opstruktivne kardiomiopatije.
During controlled clinical studies in healthy subjects, once daily doses up to 320 mg of Ipreziv were administered for 7 days and were well tolerated. 
320 mg Ipreziva bile su primijenjene jedanput na dan tijekom 7 dana i dobro su se podnosile.
As there is limited experience of use of Ipreziv in patients with mild to moderate hepatic impairment close monitoring is recommended and consideration should be given to 20 mg as a starting dose (see section 5.2). 
Budući je iskustvo s primjenom Ipreziva u bolesnika s blagim do umjerenim oštećenjem funkcije jetre ograničeno, preporučuje se pažljiv nadzor tih bolesnika, a može se razmotriti i primjena 20 mg kao početne doze (vidjeti dio 5.2).
Takeda Pharma A/S, Dybendal Alle 10, 2630 Taastrup, Denmark Manufacturer: 
Nositelj odobrenja za stavljanje lijeka u promet: Takeda Pharma A/S, Dybendal Alle 10, 2630 Taastrup, Danska
Blockade of the AT1 receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increases in plasma renin activity and angiotensin II circulating levels do not overcome the antihypertensive effect of azilsartan. 
Blokada receptora AT1 inhibira negativnu regulatornu povratnu spregu angiotenzina II na ilučenje renina, ali posljedično pojačanje aktivnosti renina u plazmi i povišenje razine cirkulirajućeg angiotenzina II ne mogu nadvladati antihipertenzivni učinak azilsartana.
Ipreziv has not been studied in patients with severe hepatic impairment. 
Ipreziv nije ispitan u bolesnika s teškim oštećenjem funkcije jetre.
Coadministration of Ipreziv with diuretics, such as chlortalidone, resulted in a greater incidence of creatinine elevations, an observation consistent with that of other angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors. 
Istovremena primjena Ipreziva s diureticima, kao što je klortalidon, rezultirala je većom incidencijom povišenja kreatinina i to je opažanje sukladno onome s drugim antagonistima receptora angiotenzina II i inhibitorima angiotenzin-konvertirajućeg enzima.
There was no evidence of QT/QTc prolongation at a dose of 320 mg of Ipreziv. 
Nije bilo dokaza da Ipreziv u dozi od 320 mg produljuje QT/QTc interval.
Dose dependent adverse events including dizziness, hypotension and serum creatinine elevations were more frequent with diuretic coadministration compared with Ipreziv alone, while hypokalemia was less frequent compared with diuretic alone. 
Nuspojave ovisne o dozi uključujući omaglicu, hipotenziju i povišenje kreatinina u serumu bile su češće kod istovremene primjene diuretika nego kad se Ipreziv primjenjivao sam, dok je hipokalemija bila rjeđa u usporedbi s primjenom samo diuretika.
- For patients such as the very elderly (75 years and above) your doctor may recommend a lower 
- Bolesnicima, kao što su vrlo stari bolesnici (u dobi od 75 ili više godina), liječnik može preporučiti nižu početnu dozu od 20 mg jedanput na dan.
Ipreziv is unlikely to have an effect on driving or using machines. 
Ipreziv najvjerojatnije neće utjecati na sposobnost upravljanja vozilima i rada na strojevima.
Blood creatine phosphokinase increased Blood creatinine increased Blood uric acid increased / Hyperuricemia 
Pretrage često manje često povišena kreatin fosfokinaza u krvi povišen kreatinin u krvi povišena mokraćna kiselina u krvi / hiperuricemija
Store Ipreziv in the original package in order to protect it from light and moisture. 
Čuvajte Ipreziv u originalnom pakiranju radi zaštite od svjetlosti i vlage.
In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-aldosterone system (e.g. patients with congestive heart failure, severe renal impairment or renal artery stenosis), treatment with medicinal products that affect this system, such as angiotensinconverting enzyme inhibitors and angiotensin II receptor antagonists, has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure. 
U bolesnika čiji krvožilni tonus i funkcija bubrega ovise pretežno o djelovanju renin-angiotenzinaldosteronskog sustava (npr. bolesnici s kongestivnim zatajenjem srca, teškim oštećenjem funkcije bubrega ili stenozom bubrežne arterije), liječenje lijekovima koji utječu na taj sustav, poput inhibitora angiotenzin-konvertirajućeg enzima i antagonista receptora angiotenzina II, povezuje se s akutnom hipotenzijom, azotemijom, oligurijom i, u rijetkim slučajevima, zatajenjem funkcije bubrega.
Mechanism of action and pharmacodynamic effect Azilsartan medoxomil is an orally active prodrug that is rapidly converted to the active moiety, azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the AT1 receptor in multiple tissues (see section 5.2). 
Azilsartanmedoksomil je peroralno djelatan predlijek koji se brzo konvertira do djelatnog oblika, azilsartana, koji selektivno antagonistički djeluje na učinke angiotenzina II time što blokira njegovo vezanje za receptor AT1 u raznim tkivima (vidjeti dio 5.2).
Do NOT take Ipreziv if you - are allergic (hypersensitive) to azilsartan medoxomil or any of the other ingredients of Ipreziv (see section 6). 
NEMOJTE uzimati Ipreziv ako ste - alergični (preosjetljivi) na azilsartanmedoksomil ili bilo koji drugi sastojak lijeka Ipreziv
Hypotension in volume- and /or salt-depleted patients In patients with marked volume- and/or salt-depletion (e.g. patients with vomiting, diarrhoea or taking high doses of diuretics) symptomatic hypotension could occur after initiation of treatment with Ipreziv. 
Hipotenzija u bolesnika sa smanjenim volumenom i/ili nedostatkom elektrolita Bolesnici s izrazito smanjenim volumenom i/ili nedostatkom elektrolita (npr. bolesnika koji povraćaju, imaju proljev ili uzimaju visoke doze diuretika) u početku liječenja Iprezivom mogu razviti simptomatsku hipotenziju.
- Heparin (a medicine for thinning the blood) - Diuretics (water tablets) - Aliskiren or other medicines to lower your blood pressure (angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, such as enalapril, lisinopril, ramipril or valsartan, 
- diuretike (tablete za mokrenje) - aliskiren ili druge lijekove za sniženje krvnog tlaka (inhibitor angiotenzin konvertirajućeg enzima ili antagonist receptora angiotenzina II, poput enalaprila, lizinoprila, ramiprila ili valsartana, telmisartana, irbesartana).
Activated renin-angiotensin-aldosterone system 
Dvostruka blokada renin-angiotenzin-aldosteronskog sustava (RAAS)
For patients with possible depletion of intravascular volume or salt depletion (e.g. patients with vomiting, diarrhoea or taking high doses of diuretics), Ipreziv should be initiated under close medical supervision and consideration can be given to 20 mg as a starting dose (see section 4.4). 
(npr. bolesnici koji povraćaju, imaju proljev ili uzimaju visoke doze diuretika), Ipreziv treba početi primjenjivati uz strogi medicinski nadzor, a može se razmotriti i primjena 20 mg kao početne doze (vidjeti dio 4.4).
Dual blockade of the renin-angiotensin-aldosterone system (RAAS) There is evidence that the concomitant use of ACE inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). 
Dvostruka blokada renin-angiotenzin-aldosteronskog sustava (RAAS) Postoje dokazi da istodobna primjena ACE inhibitora, blokatora angiotenzin II receptora ili aliskirena povećava rizik od hipotenzije, hiperkalemije i smanjene bubrežne funkcije (uključujući akutno zatajenje bubrega).
Azilsartan medoxomil is rapidly hydrolysed to the active moiety azilsartan by esterases in the gastrointestinal tract and/or during drug absorption (see section 5.2). 
Azilsartanmedoksomil brzo se hidrolizira do djelatnog oblika azilsartana zbog esteraza u gastrointestinalnom traktu i/ili tijekom apsorpcije lijeka (vidjeti dio 5.2).
Administration of Ipreziv for up to 5 days in subjects with mild (Child-Pugh A) or moderate (ChildPugh B) hepatic impairment resulted in slight increase in azilsartan exposure (AUC increased by 1.3 to 1.6 fold, see section 4.2). 
Pugh B) oštećenjem funkcije jetre dovela je do blagog povećanja izloženosti azilsartana (AUC povećan za 1,3 do 1,6 puta, vidjeti dio 4.2).
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 
U slučaju bilo kakvih nejasnoća ili pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku ili ljekarniku
EU/1/11/735/001 14 tablets EU/1/11/735/002 28 tablets EU/1/11/735/012 30 tablets EU/1/11/735/003 56 tablets EU/1/11/735/013 90 tablets EU/1/11/735/004 98 tablets 
EU/1/11/735/001 14 tableta EU/1/11/735/002 28 tableta EU/1/11/735/012 30 tableta EU/1/11/735/003 56 tableta EU/1/11/735/013 90 tableta EU/1/11/735/004 98 tableta
Ipreziv is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely. 
Ako želite dojiti, liječnik Vam može odabrati drugu terapiju, osobito ako je Vaše dijete novorođenče ili nedonošče.
EU/1/11/735/016 14 tablets EU/1/11/735/009 28 tablets EU/1/11/735/017 30 tablets EU/1/11/735/010 56 tablets EU/1/11/735/018 90 tablets EU/1/11/735/011 98 tablets 
EU/1/11/735/016 14 tableta EU/1/11/735/009 28 tableta EU/1/11/735/017 30 tableta EU/1/11/735/010 56 tableta EU/1/11/735/018 90 tableta EU/1/11/735/011 98 tableta
Placebo at 0.05 level within the framework of the step-wise analysis † Significant difference vs. Comparator(s) at 0.05 level within the framework of the step-wise analysis # Maximum dose achieved in study 2. 
† Značajna razlika u odnosu na aktivnu kontrolu (kontrole) pri razini značajnosti od 0,05 unutar okvira stupnjevite (engl. step-wise) analize.
Small mean increases of serum uric acid were observed with Ipreziv (10.8 µmol/l) compared with placebo (4.3 µmol/l). 
Mokraćna kiselina Opažena su mala prosječna povišenja mokraćne kiseline u serumu uz primjenu Ipreziva (10,8 µmol/l)
EU/1/11/735/005 14 tablets EU/1/11/735/006 28 tablets EU/1/11/735/014 30 tablets EU/1/11/735/007 56 tablets EU/1/11/735/015 90 tablets EU/1/11/735/008 98 tablets 
EU/1/11/735/005 14 tableta EU/1/11/735/006 28 tableta EU/1/11/735/014 30 tableta EU/1/11/735/007 56 tableta EU/1/11/735/015 90 tableta EU/1/11/735/008 98 tableta
The blood pressure lowering effect of Ipreziv was also maintained throughout the 24-hour dosing interval. 
Učinak Ipreziva na sniženje krvnog tlaka održao se tijekom cijelog 24
Caution should be exercised in hypertensive patients with severe renal impairment, congestive heart failure or renal artery stenosis, as there is no experience of use of Ipreziv in these patients (see sections 4.2 and 5.2). 
Potreban je oprez u preosjetljivih bolesnika s teškim oštećenjem funkcije bubrega, kongestivnim zatajenjem srca ili stenozom bubrežne arterije, jer ne postoji iskustvo s primjenom Ipreziva u tih bolesnika (vidjeti dio 4.2 i 5.2).
Ipreziv has not been studied in patients with severe hepatic impairment and therefore its use is not recommended in this patient group (see sections 4.2 and 5.2). 
Ipreziv nije ispitan u bolesnika s teškim oštećenjem funkcije jetre i stoga se njegova primjena ne preporučuje u ove skupine bolesnika (vidjeti dio 4.2 i 5.2).
Caution should be exercised in hypertensive patients with congestive heart failure as there is no experience of use of Ipreziv in these patients (see section 4.4). 
Potreban je oprez u bolesnika s hipertenzijom i kongestivnim zatajenjem srca, jer ne postoji iskustvo s primjenom Ipreziva u ovih bolesnika (vidjeti dio 4.4).
In preclinical safety studies, azilsartan medoxomil and M-II, the major human metabolite, were examined for repeated-dose toxicity, reproduction toxicity, mutagenicity and carcinogenicity. 
U pretkliničkim ispitivanjima sigurnosti bila je ispitana toksičnost ponovljene doze, reproduktivna toksičnost, mutagenost i kancerogenost azilsartanmedoksomila i M-II, glavnog metabolita u ljudi.
When Ipreziv was coadministered with chlortalidone, the frequencies of blood creatinine increased and hypotension were increased from uncommon to common. 
Kad se Ipreziv primjenjivao istovremeno s klortalidonom, manje česta povišenja kreatinina u krvi i hipotenzija postali su česti.
Cartons containing aluminum blisters packs integrated with desiccant. 
6.5 Vrsta i sadržaj spremnika Kutije koje sadrže aluminijska blister pakiranja s ugrađenim sredstvom za sušenje.
Exposure to angiotensin II receptor antagonist therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3). 
Poznato je da izlaganje terapiji antagonistima receptora angiotenzina II tijekom drugog ili trećeg tromjesečja ima fetotoksično djelovanje u ljudi (smanjenu funkciju bubrega, oligohidramnion, zakašnjelu osifikaciju lubanje) i toksično djelovanje na novorođenčad (zatajenje bubrega, hipotenzija,
INFORMATION IN BRAILLE Ipreziv 40 mg 
16. PODACI NA BRAILLEOVOM PISMU Ipreziv 40 mg
Ipreziv has not been studied in patients with severe hepatic impairment and therefore its use is not recommended in this patient group (see sections 4.4 and 5.2). 
Ipreziv nije ispitan u bolesnika s teškim oštećenjem funkcije jetre te se stoga ne preporučuje njegova primjena u te skupine bolesnika (vidjeti dio 4.4 i 5.2).
INFORMATION IN BRAILLE Ipreziv 80 mg 
16. PODACI NA BRAILLEOVOM PISMU Ipreziv 80 mg
The incidence of elevations in serum creatinine following treatment with Ipreziv was similar to placebo in the randomised placebo-controlled monotherapy studies. 
U randomiziranim, placebom kontroliranim ispitivanjima monoterapije, incidencija povišenja kreatinina u serumu nakon liječenja Iprezivom bila je slična onoj uz placebo.
NAME OF THE MEDICINAL PRODUCT Ipreziv 40 mg tablets 
NAZIV LIJEKA Ipreziv 40 mg tablete
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription 
UVJETI ILI OGRANIČENJA VEZANI UZ OPSKRBU I PRIMJENU
Non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid > 3 g/day), and non-selective NSAIDs When angiotensin II receptor antagonists are administered simultaneously with NSAIDs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. 
Kad se antagonisti receptora angiotenzina II primjenjuju istovremeno s NSAIL (npr. selektivnim COX-2 inhibitorima, acetilsalicilnom kiselinom (> 3 g na dan) i neselektivnim NSAIL), može doći do slabljenja antihipertenzivnog učinka.
INFORMATION IN BRAILLE Ipreziv 20 mg 
16. PODACI NA BRAILLEOVOM PISMU Ipreziv 20 mg
- If you suffer from other coexisting illnesses such as severe kidney disease or heart failure your doctor will decide on the most appropriate starting dose. 
- Ako istovremeno bolujete od drugih bolesti, poput teške bolesti bubrega ili zatajenja srca,
Ipreziv was compared with placebo and active comparators in two 6-week randomized, double blind studies. 
U dva randomizirana, dvostruko slijepa ispitivanja u trajanju od 6 tjedana, Ipreziv je bio uspoređen s placebom i aktivnom kontrolom.
Caution should be exercised in hypertensive patients with severe renal impairment and end stage renal disease as there is no experience of use of Ipreziv in these patients (see sections 4.4 and 5.2). 
Potreban je oprez u bolesnika s hipertenzijom i teškim oštećenjem funkcije bubrega ili završnim stadijem bubrežne bolesti, jer nema iskustva s primjenom Ipreziva u tih bolesnika (vidjeti dio 4.4 i 5.2).
- If you suffer from mild or moderate liver disease your doctor may recommend a lower starting 
- Ako bolujete od blage do umjerene bolesti jetre, liječnik Vam može preporučiti nižu početnu dozu od 20 mg jedanput na dan.
What Ipreziv looks like and contents of the pack Ipreziv are white round tablets debossed “ASL” on one side and either “20”, “40” or “80” on the other. 
Ipreziv su bijele okrugle tablete s utisnutom oznakom “ASL” na jednoj strani i “20”, “40” ili “80” na drugoj.
(medicines to relieve pain and inflammation) - Aspirin (acetylsalicyclic acid) if taking more than 3 g per day (medicine to relieve pain and 
- litij (lijek za tegobe s mentalnim zdravljem) - nesteroidne protuupalne lijekove, kao što su ibuprofen, diklofenak ili celekoksib (lijekovi za ublažavanje bolova i upale) - aspirin (acetilsalicilna kiselina), ako uzimate više od 3 g na dan (lijek za ublažavanje bola i upale)
See also information under the heading “Do not take Ipreziv”. 
Vidjeti također informacije pod naslovom “Nemojte uzimati Ipreziv” Morate obavijestiti liječnika ako mislite da ste trudni (ili biste mogli zatrudnjeti).
Rare side effects affecting less than 1 in 1000 people: - Changes in blood test results including decreased levels of a protein in the red blood cells 
- promjere rezultata krvnih pretraga uključujući snižene razine jednog proteina u crvenim krvnim stanicama (hemoglobina).
Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of lithium and angiotensin-converting enzyme inhibitors. 
Litij Tijekom istovremene primjene litija i inhibitora angiotenzin-konvertirajućeg inhibitora zabilježena su reverzibilna povećanja koncentracije litija.
What Ipreziv contains - The active substance is azilsartan medoxomil (as potassium) either 20 mg, 40 mg or 80 mg - The other ingredients are mannitol, fumaric acid, sodium hydroxide, hydroxypropylcellulose, 
SADRŽAJ PAKIRANJA I DRUGE INFORMACIJE Što Ipreziv sadrži - Djelatna tvar je azilsartanmedoksomil (u obliku kalijeve soli) od 20 mg, 40 mg ili 80 mg
NAME OF THE MEDICINAL PRODUCT Ipreziv 20 mg tablets 
NAZIV LIJEKA Ipreziv 20 mg tablete
- have severe liver disease - have heart problems (including heart failure, recent heart attack) - have ever had a stroke - have low blood pressure or feel dizzy or lightheaded - are vomiting, have recently had severe vomiting, or have diarrhoea - have elevated levels of potassium in your blood - have a disease of the adrenal gland called primary hyperaldosteronism - have been told that you have a narrowing of the valves in your heart (called “aortic or mitral valve stenosis”) or that the thickness of your heart muscle is abnormally increased (called 
- ako imate povišene razine kalija u krvi - ako imate bolest nadbubrežnih žlijezda koja se zove primarni hiperaldosteronizam - ako su Vam rekli da imate suženje srčanih zalistaka (što se zove “aortalna ili mitralna stenoza”)
Common side effects affecting less than 1 in 10 people: - Dizziness - Diarrhoea - Increased blood creatine phosphokinase (an indicator of muscle damage). 
- omaglica - proljev - povišena kreatin fosfokinaza u krvi (pokazatelj oštećenja mišića).
NAME OF THE MEDICINAL PRODUCT Ipreziv 80 mg tablets 
NAZIV LIJEKA Ipreziv 80 mg tablete
Clinic SBP: LS Mean Change from Baseline (BL) to Week 6 (mm Hg) (LOCF) Study 1 
tjedna (mm Hg) (LOCF) Ispitivanje 1
NAME OF THE MEDICINAL PRODUCT Ipreziv 40 mg tablets azilsartan medoxomil 
NAZIV LIJEKA Ipreziv 40 mg tablete azilsartanmedoksomil
NAME OF THE MEDICINAL PRODUCT Ipreziv 20 mg tablets azilsartan medoxomil 
NAZIV LIJEKA Ipreziv 20 mg tablete azilsartanmedoksomil
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 80 mg of azilsartan medoxomil (as potassium). 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna tableta sadrži 80 mg azilsartanmedoksomila (u obliku kalijeve soli).
NAME OF THE MEDICINAL PRODUCT Ipreziv 80 mg tablets azilsartan medoxomil 
NAZIV LIJEKA Ipreziv 80 mg tablete azilsartanmedoksomil
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg of azilsartan medoxomil (as potassium). 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna tableta sadrži 20 mg azilsartanmedoksomila (u obliku kalijeve soli).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 40 mg of azilsartan medoxomil (as potassium). 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna tableta sadrži 40 mg azilsartanmedoksomila (u obliku kalijeve soli).
However some people may feel tired or dizzy when taking Ipreziv and if this happens to you, do not drive or use any tools or machines. 
Međutim, neke osobe mogu osjećati umor ili omaglicu dok uzimaju Ipreziv.
azilsartan medoxomil 
azilsartanmedoksomil
“obstructive hypertrophic cardiomyopathy”). 
Aortalna i mitralna stenoza, opstruktivna hipertrofična kardiomiopatija
Consequently, uptitration of Ipreziv and concomitant therapy may be needed more frequently for blood pressure control in black patients. 
Posljedično tome, za kontrolu krvnog tlaka u bolesnika crne rase može biti potrebno postupno povećavati dozu Ipreziva i istovremeno davati dodatnu terapiju.
Ipreziv is for oral use. 
Ipreziv se uzima kroz usta.
The incidence of adverse reactions with Ipreziv was not affected by gender, age, or race. 
Spol, dob i rasa nisu utjecali na incidenciju nuspojava Ipreziva.